Randomized phase II study of gemcitabine and S-1 combination therapy versus gemcitabine and nanoparticle albumin-bound paclitaxel combination therapy as neoadjuvant chemotherapy for resectable/borderline resectable pancreatic ductal adenocarcinoma (PDAC-GS/GA-rP2, CSGO-HBP-015)

BACKGROUND: Pancreatic ductal adenocarcinoma (PDAC) is a lethal disease, and multimodal strategies, such as surgery plus neoadjuvant chemotherapy (NAC)/adjuvant chemotherapy, have been attempted to improve survival in patients with localized PDAC. To date, there is one prospective study providing ev...

Descripción completa

Detalles Bibliográficos
Autores principales: Yamada, Daisaku, Kobayashi, Shogo, Takahashi, Hidenori, Akita, Hirofumi, Yamada, Terumasa, Asaoka, Tadafumi, Shimizu, Junzo, Takeda, Yutaka, Yokoyama, Shigekazu, Tsujie, Masanori, Tomokuni, Akira, Tanemura, Masahiro, Morimoto, Osakuni, Murakami, Masahiro, Kim, Yongkook, Nakahira, Shin, Hama, Naoki, Sugimoto, Keishi, Hashimoto, Kazuhiko, Doki, Yuichiro, Eguchi, Hidetoshi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8394677/
https://www.ncbi.nlm.nih.gov/pubmed/34446057
http://dx.doi.org/10.1186/s13063-021-05541-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8394677/
https://www.ncbi.nlm.nih.gov/pubmed/34446057
http://dx.doi.org/10.1186/s13063-021-05541-w

Ejemplares similares